An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Lilly’s Retatrutide Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial On May 21, Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy […]
Pharma Friday – May 22, 2026
Join the Global Movement Advancing Endocrine Science and Medicine
Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.